Abstract
We recently conducted a comprehensive review of the psychiatric inclusion and exclusion criteria used in 170 placebo-controlled antidepressant efficacy trials (AETs) that were published between 1995 and 2014. In conducting this literature review, we identified a number of instances in which the descriptions of the inclusion/exclusion criteria were vague, redundant, or difficult to interpret. In the present article, we describe nine problems we encountered in our literature review. We recommend that future publications follow the examples found in a few studies in which the inclusion/exclusion criteria are clearly defined and listed in a table.
Similar content being viewed by others
References
Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice. Am J Psychiatry. 2002;159:469–73.
van der Lem R, et al. The generalizability of antidepressant efficacy trials to routine psychiatric out-patient practice. Psychol Med. 2011;41:1353–63.
Wisniewski SR, et al. Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry. 2009;166:599–607.
Zetin M, Hoepner CT. Relevance of exclusion criteria in antidepressant clinical trials: a replication study. J Clin Psychopharmacol. 2007;27:295–301.
Zimmerman M, et al. Have treatment studies of depression become even less generalizable? A review of the inclusion and exclusion criteria in placebo controlled antidepressant efficacy trials published during the past 20 years. Mayo Clin Proc. 2015;90:1180–6.
Arana G, et al. Dexamethasone for the treatment of depression: a randomized, placebo-controlled, double-blind trial. Am J Psychiatry. 1995;152:265–7.
Cohn C, et al. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. J Clin Psychiatry. 1996;57:15–8.
Coleman C, et al. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther. 2001;23:1040–58.
Croft H, et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther. 1999;21:643–58.
Binneman B, et al. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry. 2008;165:617–20.
Bjerkenstedt L, et al. Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo controlled multi-center study in outpatients. Eur Arch Psychiatry Clin Neurosci. 2005;255:40–7.
Lecrubier Y, et al. Efficacy of St. John’s Wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. 2002;159:1361–6.
Corrigan M, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety. 2000;11:58–65.
Gommoll C, et al. A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder. J Drug Assess. 2014;3:10–9.
Papakostas G, et al. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. J Clin Psychiatry. 2012;73:1541–7.
Mischoulon D, et al. A double-blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression. J Clin Psychiatry. 2015;76:54–61.
Rickels K, et al. Zalospirone in major depression: a placebo-controlled multicenter study. J Clin Psychopharmacol. 1996;16:212–7.
Akiskal H, et al. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord. 2000;59:S5–30.
Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord. 1998;50:143–51.
Angst J. Problems in the current concepts and definitions of bipolar disorders. World Psychiatry. 2011;10:191–2.
Benazzi F. Prevalence of bipolar II disorder in outpatient depression: a 203-case study in private practice. J Affect Disord. 1997;43:163–6.
Katila H, et al. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry. 2013;21:769–84.
Mischoulon D, et al. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-l-methionine (SAMe) versus escitalopram in major depressive disorder. J Clin Psychiatry. 2014;75:370–6.
Olie J, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol. 2007;10:661–73.
Raskin J, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry. 2007;164:900–9.
Sambunaris A, et al. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J Clin Psychopharmacol. 2014;34:47–56.
Costa e Silva J, et al. Placebo-controlled study of tianeptine in major depressive episodes. Pharmacopsychiatry. 1997;35:24–39.
Dube S, et al. A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression. J Psychiatr Res. 2010;44:356–63.
Feiger A, et al. A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder. CNS Spectr. 2009;14:41–50.
Nierenberg A, et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin. 2007;23:401–16.
Nemeroff C, Thase M. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. J Psychiatr Res. 2007;41:351–9.
Walczak D, et al. The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients. Ann Clin Psychiatry. 1996;8:139–51.
Weisler R, et al. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr. 2009;14:299–313.
Jain R, et al. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2012;16:313–21.
Kalb R, et al. Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. Pharmacopsychiatry. 2001;34:96–103.
Zhang Z, et al. The effectiveness of carbamazepine in unipolar depression: a double-blind, randomized, placebo-controlled study. J Affect Disord. 2008;109:91–7.
Boyer P, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008;23:243–53.
Clayton A, et al. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2013;74:1010–7.
DeMartinis N, et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007;68:677–88.
Feiger A, et al. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry. 2006;67:1354–61.
Hewett K, et al. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol. 2010;24:1209–16.
Newton-Howes G, et al. Influence of personality on the outcome of treatment in depression: systematic review and meta-analysis. J Pers Disord. 2014;28:577–93.
Croft H, et al. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2014;75:e1291–8.
Khan A, et al. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry. 2011;72:441–7.
Feighner J, Overo K. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry. 1999;60:824–30.
Boulenger J, Loft H, Olsen C. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014;29:138–49.
Clayton A, et al. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. Int Clin Psychopharmacol. 2003;18:151–6.
Ferguson J, Wesnes K, Schwartz G. Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol. 2003;18:9–14.
Amsterdam J. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry. 2003;64:208–14.
Amsterdam J, Brunswick D, Hundert M. A single-site, double-blind, placebo-controlled, dose-ranging study of YKP10A: a putative, new antidepressant. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:1333–8.
Asnis G, et al. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013;74:242–8.
Bremner J. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry. 1995;56:519–25.
Burke W, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry. 2002;63:331–6.
Akhondzadeh S, et al. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytotherapy Res: PTR. 2005;19:148–51.
Bielski R, et al. Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study. J Clin Psychiatry. 2008;69:571–7.
Alvarez E, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012;15:589–600.
Baldwin D, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012;22:482–91.
Bortnick B, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disorders. 2011;128:83–94.
Cunningham L. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Ann Clin Psychiatry. 1997;9:157–64.
Uebelhack R, et al. Efficacy and tolerability of Hypericum extract STW 3-VI in patients with moderate depression: a double-blind, randomized, placebo-controlled clinical trial. Adv Ther. 2004;21:265–75.
Montgomery S, et al. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2013;74:363–9.
Fava M, et al. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Ann Clin Psychiatry. 1998;10:145–50.
Richou H, et al. A multicentre, double-blind, clomipramine-controlled efficacy and safety study of org 3770. Hum Psychopharmacol. 1995;10:263–71.
Lopresti A, et al. Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study. J Affect Disord. 2014;167:368–75.
Kennedy S, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2006;16:93–100.
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9.
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
Wang G, et al. A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder. Neuropsychiatr Dis Treat. 2014;10:201–16.
Mahableshwarkar A, et al. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacol. 2015;232:2061–70.
Bakish D, et al. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J Psychiatry Neurosci. 2014;39:40–9.
Mahableshwarkar A, et al. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013;29:217–26.
Brauzer B, Goldstein BJ. Symptomic volunteers: Another patient dimension for clinical trials. J Clin Pharmacology. 1973;13:89–98.
Breckenridge JS, et al. Solicitations of elderly depressives for treatment outcome research: a comparison of referral sources. J Consult Clin Psychol. 1985;53:552–4.
Miller CA, Hooper CL, Bakish D. A comparison of patients with major depressive disorder recruited through newspaper advertising versus consultation referrals for clinical drug trials. Psychopharmacol Bull. 1997;33:69–73.
Rapaport MH, et al. A comparison of descriptive variables for clinical patients and symptomatic volunteers with depressive disorders. J Clin Psychopharmacol. 1996;16:242–6.
Covi L, et al. Symptomatic volunteers in multicenter drug trails. Neuropsychopharmacol. 1979;3:521–33.
Partonen T, Sihvo S, Lonnqvist JK. Patients excluded from antidepressant efficacy trial. J Clin Psychiatry. 1996;57:572–5.
Keitner G, Posternak M, Ryan C. How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial? J Clin Psychiatry. 2003;64:1091–3.
Stahl S, et al. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry. 2010;71:616–26.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
None.
Conflicts of interest
M. Zimmerman has served on advisory boards for F Hoffmann-La Roche, Genentech, and Lundbeck; has received research support from Azevan and Eli Lilly; and has prepared educational material for Otsuka. Matthew Multach, Emily Walsh, Lia K. Rosenstein, Douglas Gazarian, and Heather L. Clark have no conflicts of interest to declare.
Rights and permissions
About this article
Cite this article
Zimmerman, M., Multach, M., Walsh, E. et al. Problems in the Descriptions of the Psychiatric Inclusion and Exclusion Criteria in Publications of Antidepressant Efficacy Trials: A Qualitative Review and Recommendations for Improved Clarity. CNS Drugs 30, 185–191 (2016). https://doi.org/10.1007/s40263-016-0314-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40263-016-0314-y